Foghorn Therapeutics Inc. (FHTX) - 10-Q Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system. This report covers the quarterly period ended September 30, 2025. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. It operates as a single segment focused on its proprietary Gene Traffic Control platform and a strategic collaboration with Eli Lilly and Company ("Lilly").
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $8,153 | $7,808 | $21,662 | $19,746 |
| Net Loss | $(15,849) | $(19,122) | $(52,619) | $(67,117) |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.31) | $(0.84) | $(1.28) |
| Operating Expenses | $26,654 | $31,660 | $84,173 | $98,424 |
| Cash & Cash Equivalents | $89,334 | $55,454 | (Balance Sheet Data) | |
| Marketable Securities | $90,944 | $188,293 | ||
| Total Liquidity (Cash + Securities) | $180,278 | $243,747 | (As of Sept 30, 2025) | |
| Accumulated Deficit | $(610,803) | $(558,184) | (As of Sept 30, 2025) |
Debt & Liquidity: The Company has no long-term debt. Total liabilities as of September 30, 2025, were $294.6 million, primarily consisting of deferred revenue ($258.4 million) and operating lease liabilities ($22.5 million). Management expects current cash and marketable securities to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by 4.4% in Q3 2025 ($8.2M) compared to Q3 2024 ($7.8M), and by 9.7% for the nine-month period ($21.7M vs. $19.7M). This is driven by the continued recognition of the upfront payment from the Lilly Collaboration Agreement.
- Expense Reduction: Total operating expenses decreased by 15.8% in Q3 2025 ($26.7M) compared to Q3 2024 ($31.7M). For the nine months ended September 30, 2025, expenses decreased by 14.5% ($84.2M vs. $98.4M).
- R&D Drivers: The decrease in R&D expenses was primarily due to the discontinuation of the independent development of FHD-286 (saving $3.4M in Q3 and $8.4M in 9M) and a lease modification in June 2025 that reduced facility costs. These savings were partially offset by increased costs for the Lilly-partnered FHD-909 Phase 1 trial.
- Impairment: Unlike the prior year, there were no impairment charges in 2025. In the nine months ended September 30, 2024, the Company recorded a $2.4 million non-cash impairment charge related to subleased office space.
- Interest Income: Interest income decreased to $2.0M in Q3 2025 from $3.5M in Q3 2024, reflecting a lower average balance of marketable securities.
Guidance, Outlook, and Risks
- Outlook: The Company expects to continue incurring significant operating losses. Expenses are projected to increase as the Phase 1 dose escalation study of FHD-909 advances and enrollment increases. No specific financial guidance was provided beyond the expectation that current liquidity is sufficient for at least 12 months.
- Key Developments:
- FHD-909: The Phase 1 study for this selective SMARCA2 inhibitor (partnered with Lilly) dosed its first patient in October 2024. Costs are shared 50/50 with Lilly.
- FHD-286: Development was discontinued in December 2024 for relapsed/refractory AML and uveal melanoma.
- Lease Restructuring: In June 2025, the Company entered a new lease in Watertown, MA, and amended its Cambridge lease, reducing fixed payments by $8.5 million and shortening the term for a portion of the space.
- Risks & Contingencies:
- Capital Requirements: The Company requires substantial additional funding to support operations and clinical trials. Failure to raise capital could force delays or termination of programs.
- Going Concern: While currently funded for 12 months, the Company has an accumulated deficit of $610.8 million and relies on future financing, collaborations, or licensing.
- Regulatory & Clinical: Risks include the inability to obtain regulatory approval for FHD-909 or future candidates, and the uncertainty of clinical trial results.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $180.3 million in cash and marketable securities against the projected burn rate, especially given the upcoming costs for the FHD-909 Phase 1 trial.
- Revenue Recognition: Confirm the methodology for recognizing the $300 million Lilly upfront payment over the performance period and the impact of potential changes in estimated total costs.
- Lease Obligations: Review the details of the new Watertown lease and the amended Cambridge lease to understand future fixed cost commitments and the timing of the move.
- Program Status: Monitor the enrollment and safety data for the FHD-909 Phase 1 trial, as this is the primary driver of future R&D spend and potential milestone revenue.
- Capital Markets: Assess the Company's ability to raise additional equity or debt in the current market environment, given its status as a smaller reporting company with a history of losses.